Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22160TDB-ST

Select Item

Collagenase-3 plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC, and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization, and ossification.

The Collagenase 3 pipeline market research report provides comprehensive information on the Collagenase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Therapy Areas in the Collagenase 3 Pipeline Products Market

The key therapy areas in the Collagenase 3 pipeline products market are musculoskeletal disorders, cardiovascular, central nervous system, genetic disorders, infectious disease, oncology, respiratory, and toxicology.

Collagenase 3 Pipeline Products Market Analysis by Therapy Areas

Collagenase 3 Pipeline Products Market Analysis by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanisms of Action in the Collagenase 3 Pipeline Products Market

The key mechanism of action in the Collagenase 3 pipeline products market is Collagenase 3 Inhibitor.

Key Routes of Administration in the Collagenase 3 Pipeline Products Market

The key routes of administration in the Collagenase 3 pipeline products market are intramuscular, nasal, subcutaneous, and intraarticular.

Collagenase 3 Pipeline Products Market Analysis by Routes of Administration

Collagenase 3 Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Collagenase 3 Pipeline Products Market

The key molecule types in the Collagenase 3 pipeline products market are polysaccharide, small molecule, antisense RNAi oligonucleotide, and protein.

Collagenase 3 Pipeline Products Market Analysis by Molecule Types

Collagenase 3 Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the Collagenase 3 Pipeline Products Market

The major companies in the Collagenase 3 pipeline products market are Aquilus Pharmaceuticals Inc, Avantyx Pharmaceuticals LLC, Paradigm Biopharmaceuticals Ltd, Pharmahungary Group, and SteroTherapeutics LLC.

Collagenase 3 Pipeline Products Market Analysis by Companies

Collagenase 3 Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Collagenase 3 Pipeline Products Market Report Overview

Key Therapy Areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease, Oncology, Respiratory, and Toxicology
Key Mechanisms of Action Collagenase 3 Inhibitor
Key Routes of Administration Intramuscular, Nasal, Subcutaneous, and Intraarticular
Key Molecule Type Polysaccharide, Small Molecule, Antisense RNAi Oligonucleotide, and Protein
Major Companies Aquilus Pharmaceuticals Inc, Avantyx Pharmaceuticals LLC, Paradigm Biopharmaceuticals Ltd, Pharmahungary Group, and SteroTherapeutics LLC

Scope

  • The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage

  • Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Aquilus Pharmaceuticals Inc
Avantyx Pharmaceuticals LLC
Paradigm Biopharmaceuticals Ltd
Pharmahungary Group
SteroTherapeutics LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Overview

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Companies Involved in Therapeutics Development

Aquilus Pharmaceuticals Inc

Avantyx Pharmaceuticals LLC

Paradigm Biopharmaceuticals Ltd

Pharmahungary Group

SteroTherapeutics LLC

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Drug Profiles

Antisense RNAi Oligonucleotides to Inhibit MMP-13 for Osteoarthritis – Drug Profile

Product Description

Mechanism Of Action

Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile

Product Description

Mechanism Of Action

History of Events

Matrix Metalloproteinase 13 (MMP-13) Inhibitors – Drug Profile

Product Description

Mechanism Of Action

History of Events

pentosan polysulfate sodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

Proteins for Rheumatoid Arthritis and Osteoarthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Dormant Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Discontinued Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) – Product Development Milestones

Featured News & Press Releases

Aug 08, 2022: MPS clinical program update and paradigm to present at the International Conference on lysosomal diseases

Jul 13, 2022: Paradigm partners with NFL Alumni Health on osteoarthritis program

Jul 06, 2022: Paradigm reports important global progress for the PARA_OA_002 phase 3 clinical trial evaluating Zilosul for osteoarthritis.

Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment

May 24, 2022: Paradigm Biopharmaceuticals spotlights potential breakthrough osteoarthritis treatment at Biological Association 3rd Annual Summit

May 05, 2022: Paradigm doses first subjects in Phase III knee osteoarthritis trial

Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program

Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S

Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.

Feb 11, 2022: International researchers highlight the need for PPS as a new adjunct therapy treatment for unmet needs of patients with MPS VI

Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia

Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference

Dec 16, 2021: PPS treatment demonstrates improvement in heart function and tissue preservation in preclinical heart failure model

Nov 23, 2021: Positive interim data from phase 2 rare disease trial presented at international medical congress

Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Aquilus Pharmaceuticals Inc, 2022

Pipeline by Avantyx Pharmaceuticals LLC, 2022

Pipeline by Paradigm Biopharmaceuticals Ltd, 2022

Pipeline by Pharmahungary Group, 2022

Pipeline by SteroTherapeutics LLC, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Other Diseases reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more